EBR Systems

EBR Systems, Inc. is a medical device company developing the WiSE Cardiac Stimulation System — a leadless, wireless pacing technology designed to deliver cardiac resynchronization therapy (CRT) to heart failure patients who cannot be treated with conventional CRT devices due to coronary sinus anatomy limitations or the failure of conventional CRT leads. According to its website at ebrsystemsinc.com, the WiSE System replaces the left ventricular lead used in conventional CRT — which must be threaded through the coronary sinus vein to pace the left side of the heart — with a miniaturized wireless electrode implanted directly into the left ventricular wall, eliminating the anatomical constraints and lead placement challenges that make conventional CRT ineffective or infeasible for a significant minority of eligible patients. EBR's wireless approach represents a fundamental innovation in cardiac resynchronization therapy delivery.

EBR Systems' WiSE technology platform, described at ebrsystemsinc.com, consists of three components: a miniaturized acoustic transmitter implanted subcutaneously in the chest, a commercially available implantable cardioverter-defibrillator (ICD) that generates and times the pacing pulses, and the WiSE electrode — a tiny device implanted in the left ventricular wall that receives ultrasound energy from the transmitter and converts it to electrical energy to stimulate cardiac muscle. The ultrasonic energy transmission system eliminates the need for a conventional transvenous lead to reach the left ventricle, enabling effective left ventricular pacing in patients where conventional lead placement is impossible due to inadequate coronary sinus anatomy or where prior CRT lead placement has failed. EBR's WiSE System has received CE Mark approval in Europe and has been the subject of U.S. clinical trials.

EBR Systems is pursuing FDA approval for the WiSE Cardiac Stimulation System in the United States through its clinical development program, which has generated compelling evidence of the system's safety and efficacy in heart failure patients who are unresponsive to or ineligible for conventional CRT. According to ebrsystemsinc.com, the company's U.S. pivotal trial results have demonstrated meaningful improvements in cardiac function and patient symptoms, supporting the regulatory case for approval of WiSE as an important new treatment option for the significant population of CRT non-responders and patients with inadequate coronary sinus anatomy. EBR Systems' combination of innovative wireless cardiac stimulation technology, CE Mark-approved commercial product, and ongoing U.S. pivotal trial positions it as a significant medical device innovator in the cardiac rhythm management market.